Close

WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in the United States

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Upperton completes build of new £7m sterile manufacturing facility

Nottingham - Leading UK contract development and manufacturing organisation (CDMO)...

Oncology start-ups urged to apply and accelerate their business with Discovery Spark

Applications open for Discovery Park’s oncology themed ‘Discovery...

2025 AI Trends & Pharma Predictions

As we navigate what the future of healthcare will...

WuXi Biologics, a global company with leading open-access biologics technology platforms, and the Worcester Business Development Corporation (WBDC) announced the successful signing of a land deal for WuXi Biologics’ clinical and commercial manufacturing facility (MFG11) in Worcester at The Reactory, a 46-acre master-planned biomanufacturing campus. The approximately 107,000-square-foot, two-story facility will be operational in 2022 and create 150 new jobs.

“As the central Massachusetts biotech community continues its growth, WuXi Biologics’ arrival in Worcester will strengthen the sector and lead to ongoing economic development,” said Lt. Governor Karyn Polito. “Years of planning and collaboration to transform an unused property into a biomanufacturing hub has led to this exciting announcement today and I appreciate the commitment of so many to making this a reality.”

“This signing solidifies our city’s proud role as an anchor in the state’s biotech corridor,” said Worcester City Manager Edward M. Augustus, Jr. “It signals not only what we currently have to offer in the life sciences sector, but also how much potential we have for the future.”

Craig Blais, the president and CEO of the WBDC, stated, “WuXi Biologics’ decision to locate its first US biomanufacturing facility in Worcester at The Reactory confirms the value of Worcester’s strong life sciences ecosystem. We expect other biotech manufacturers will soon follow their lead.”

“We are proud to join the Worcester community and greater region as a tenant of The Reactory, and I thank the city of Worcester for its collaboration,” said Dr. Chris Chen, CEO of WuXi Biologics. “Drawing from the talented workforce and impressive biotech network in Massachusetts, we stand ready and able to help our global partners advance their innovative and life-saving ideas. Together, I am confident that we have much to contribute to the biologics industry and patients worldwide.”

In March, recognizing the urgent need for personal protective equipment (PPE), WuXi Biologics sourced and donated masks to local healthcare providers to support frontline medical personnel fighting the coronavirus.

About WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of December 31, 2019, there were a total of 250 integrated projects, including 121 projects in pre-clinical development stage, 112 projects in early-phase (phase I and II) clinical development, 16 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany and Singapore exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network.

Latest stories